Aggressive lipid lowering improves the outcome after coronary artery bypass graft

In the Post Coronary Artery Bypass Graft trial, which enrolled 1351 patients, aggressive lipid-lowering therapy with lovastatin and, if needed, cholestyramine insignificantly reduced the composite clinical end point of death, myocardial infarction, need for revascularization procedures, or stroke by 18% at the end of the trial. However, at the end of the 7.5-year extended follow-up period, there was a significant 24% reduction in the composite clinical endpoint (p = 0.001).